Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers
- 1 November 2005
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 94 (3), 279-284
- https://doi.org/10.1007/s10549-005-9020-z
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2003
- Mode of action of docetaxel – a basis for combination with novel anticancer agentsCancer Treatment Reviews, 2003
- Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: The potential and the questionsSurgical Clinics of North America, 2003
- Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerThe Lancet, 2003
- Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rateBritish Journal of Cancer, 2003
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With DocetaxelJournal of Clinical Oncology, 2002
- Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinomaCancer, 2000
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Comprehensive management of locally advanced breast cancerCancer, 1990
- Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapyCancer, 1988